伏氯托品：镰状细胞病的一线希望。
Voxelotor: A Ray of Hope for Sickle Disease.
作者信息
AlDallal Salma M
机构信息
Hematology Laboratory Specialist, Amiri Hospital, Kuwait City, KWT.
出版信息
Cureus. 2020 Feb 26;12(2):e7105. doi: 10.7759/cureus.7105.
Abstract
Sickle cell disease is one challenging blood disorder, affecting around 100,000 people in the United States alone. None of the currently approved drugs can modify the underlying pathology of the disease. Voxelotor, first of its kind, is an orally administered drug that can alter the underlying disease pathology (by increasing the affinity between Hb and oxygen) and inhibit sickling of red blood cells. Several clinical trials and case series have documented the benefits and safety of voxelotor therapy in sickle cell disease. Currently, the US FDA has approved the drug for treatment of sickle cell disease and also granted the status of orphan drug.
摘要
镰状细胞病是一种具有挑战性的血液疾病，仅在美国就影响着约10万人。目前获批的药物均无法改变该疾病的潜在病理状况。伏索利度（Voxelotor）是同类药物中的首款，是一种口服药物，可改变潜在的疾病病理状况（通过增加血红蛋白与氧气之间的亲和力）并抑制红细胞镰变。多项临床试验和病例系列记录了伏索利度治疗镰状细胞病的益处和安全性。目前，美国食品药品监督管理局已批准该药物用于治疗镰状细胞病，并授予其孤儿药地位。
相似文献
1
Voxelotor: A Ray of Hope for Sickle Disease.
Cureus. 2020 Feb 26;12(2):e7105. doi: 10.7759/cureus.7105.
2
Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
Br J Clin Pharmacol. 2019 Jun;85(6):1290-1302. doi: 10.1111/bcp.13896. Epub 2019 Mar 31.
3
Voxelotor improves red blood cell functionality in children with sickle cell anaemia: An ancillary study of the HOPE-KIDS 1 trial.
EJHaem. 2024 Jan 30;5(1):125-130. doi: 10.1002/jha2.831. eCollection 2024 Feb.
4
Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor.
Ther Adv Hematol. 2021 Mar 19;12:20406207211001136. doi: 10.1177/20406207211001136. eCollection 2021.
5
Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
Pharmacotherapy. 2020 Jun;40(6):525-534. doi: 10.1002/phar.2405. Epub 2020 May 19.
6
Voxelotor: First Approval.
Drugs. 2020 Feb;80(2):209-215. doi: 10.1007/s40265-020-01262-7.
7
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14.
8
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Blood. 2019 Apr 25;133(17):1865-1875. doi: 10.1182/blood-2018-08-868893. Epub 2019 Jan 17.
9
Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease.
Front Med (Lausanne). 2022 Sep 15;9:931924. doi: 10.3389/fmed.2022.931924. eCollection 2022.
10
Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):698-710. doi: 10.1002/psp4.12780. Epub 2022 Apr 21.
引用本文的文献
1
A retrospective research of adverse event reporting system events for voxelotor based on the FAERS database.
BMC Pharmacol Toxicol. 2025 Apr 3;26(1):74. doi: 10.1186/s40360-025-00915-1.
2
Computational screening of phytochemicals present in some Nigerian medicinal plants against sickle cell disease.
Sci Rep. 2024 Nov 1;14(1):26368. doi: 10.1038/s41598-024-75078-w.
3
Roles of Pharmacists in the Management of Sickle Cell Disease in Adults: A Narrative Review.
J Pharm Technol. 2024 Apr;40(2):92-99. doi: 10.1177/87551225231222437. Epub 2024 Jan 10.
4
The Efficacy of Marijuana Use for Pain Relief in Adults With Sickle Cell Disease: A Systematic Review.
Cureus. 2022 May 13;14(5):e24962. doi: 10.7759/cureus.24962. eCollection 2022 May.
5
Genome-based therapeutic interventions for β-type hemoglobinopathies.
Hum Genomics. 2021 Jun 5;15(1):32. doi: 10.1186/s40246-021-00329-0.
6
Complement in Sickle Cell Disease: Are We Ready for Prime Time?
J Blood Med. 2021 Mar 23;12:177-187. doi: 10.2147/JBM.S287301. eCollection 2021.
7
Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease.
Orphanet J Rare Dis. 2021 Mar 23;16(1):148. doi: 10.1186/s13023-021-01781-w.
本文引用的文献
1
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14.
2
Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
Br J Clin Pharmacol. 2019 Jun;85(6):1290-1302. doi: 10.1111/bcp.13896. Epub 2019 Mar 31.
3
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Blood. 2019 Apr 25;133(17):1865-1875. doi: 10.1182/blood-2018-08-868893. Epub 2019 Jan 17.
4
Emerging pharmacotherapeutic approaches for the management of sickle cell disease.
Expert Opin Pharmacother. 2019 Feb;20(2):173-186. doi: 10.1080/14656566.2018.1548610. Epub 2018 Nov 30.
5
Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease.
Hematol Rep. 2018 May 22;10(2):7643. doi: 10.4081/hr.2018.7643. eCollection 2018 May 14.
6
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971.
7
Development and validation of an oxygen dissociation assay, a screening platform for discovering, and characterizing hemoglobin-oxygen affinity modifiers.
Drug Des Devel Ther. 2018 Jun 1;12:1599-1607. doi: 10.2147/DDDT.S157570. eCollection 2018.
8
Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access.
Am J Hematol. 2018 May 12. doi: 10.1002/ajh.25139.
9
GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions.
Clin Hemorheol Microcirc. 2018;70(1):95-105. doi: 10.3233/CH-170340.
10
Sickle cell disease.
Nat Rev Dis Primers. 2018 Mar 15;4:18010. doi: 10.1038/nrdp.2018.10.
Zotero 插件